PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies

Summary

Product: PSB202 is a novel biological entity consisting of two engineered monoclonal antibodies, an Fc-enhanced humanized type II anti-CD20 IgG1 (PSB102) and a humanized anti-CD37 IgG1 (PSB107), that target B-cells. PSB202 is manufactured to work as a single product with the two components of PSB202 enabling a distinct dual target-specific antibody directed cell killing of B-cells. Study: Multi-center-, International Phase 1a/1b (Escalation/Expansion) study in patients with indolent-, relapsed-, B-cell malignancies. The Phase 1a (Dose Escalation) part of study follows a 3+3 design.

Timeline

Start

2021-11-15

Primary completion

2023-07

Completion

2024-01

Publications

• Wang L, Liu J, Zhou K, Li Z, Zeng Y, Qian Y, Sun Y, Wu H, Roerker L, Tan P, Ma C, Zhou L, Duan X, Kang X, Zhao WL. A first-in-class bifunctional antibody targeting CD20 and CD37 remodels the immune microenvironment in relapsed or refractory B-cell malignancies. J Hematol Oncol. 2026 May 29;19(1):36. doi: 10.1186/s13045-026-01796-5.

Drugs

Indications